BMO Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and raises the price target from $50 to $70.
February 05, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on 4D Molecular Therapeutics and raises the price target from $50 to $70.
The increase in price target from $50 to $70 by a reputable analyst suggests a strong bullish outlook on the stock, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100